查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1943705

專業藥局市場－全球產業規模、佔有率、趨勢、競爭格局、機會及預測：按所有權、治療領域、地區和競爭格局分類，2021-2031年

Specialty Pharmacy Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, Segmented By Ownership, By Therapy Area, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球特藥市場預計將從 2025 年的 1,284.1 億美元成長到 2031 年的 1,928.2 億美元，複合年成長率達到 7.01%。

該細分市場專注於高成本、高管理要求的藥物療法的管理和分銷，這些療法專為患有罕見疾病、慢性病或複雜疾病的患者設計，需要特定的劑量和治療方案。市場成長的主要促進因素是全球人口老化、慢性病盛行率上升以及強大的藥物研發管線，尤其專注於孤兒藥和生物製藥。這些基本因素使得專科藥局模式中固有的專業供應鏈能力和臨床管控成為確保病人安全和治療依從性的關鍵。

市場概覽
預測期 2027-2031
市場規模：2025年 1284.1億美元
市場規模：2031年 1928.2億美元
複合年成長率：2026-2031年 7.01%
成長最快的細分市場 醫院
最大的市場 北美洲

儘管市場成長勢頭強勁，但由於治療費用高昂且嚴格的報銷通訊協定，患者難以獲得治療，因此該市場面臨許多挑戰。這些治療帶來的巨大經濟負擔對醫療系統和支付者造成了沉重壓力，也凸顯了製定強力的成本控制策略的必要性。美國管理式醫療藥房學會（Academy of Managed Care Pharmacy）的報告顯示，到2024年，專科藥物將佔藥品總支出的51%，這表明這些重要療法具有巨大的經濟影響和管理複雜性。

市場促進因素

基因療法和生物製藥的快速創新是全球專科藥房市場發展的關鍵驅動力，從根本上改變了罕見疾病和複雜疾病的治療模式。這一發展勢頭體現在大量高價值療法的研發管線中，這些療法需要專科藥房運作的核心——獨特的臨床專業知識、病患支援服務和低溫運輸物流。孤兒藥的研發投入顯著增加，確保特定患者群體能夠獲得以往難以獲得或難以企及的標靶治療。根據美國食品藥物管理局（FDA）於2025年1月發布的《2024年新藥認證報告》，罕見疾病治療藥物將佔2024年核准的前50種新藥的50%以上。這一成長凸顯了專科藥房在安全提供這些改變生命的治療方法方面發揮的關鍵作用。

同時，隨著專利到期，生物相似藥的激增正在重塑市場動態，為成熟的生物製藥品牌提供更具成本效益的替代方案。隨著重磅生物製藥失去專利保護，醫療系統和支付方正積極推廣生物相似藥的使用，以減輕專科治療日益沉重的經濟負擔，同時維持高標準的醫療服務。這種轉變不僅降低了單位成本，也透過減少經濟障礙，擴大了患者獲得重要治療方法的機會。 2025年9月，美國可及藥品協會（Association for Accessible Medicines）報告稱，生物相似藥預計在2024年為美國醫療系統節省202億美元。儘管如此，對複雜藥物的整體需求仍在推動市場擴張。美國衛生系統藥師協會（American Society of Health-System Pharmacists）在2025年指出，2024年美國藥品總支出將成長10.2%，達到8,059億美元。

市場挑戰

治療成本不斷上漲，加上嚴格的報銷通訊協定，為全球專科藥局市場的成長帶來了巨大障礙。為了控制成本，保險公司和支付方經常採取嚴格的用藥管理策略，例如強制執行階梯通訊協定和複雜的預先核准要求。這些措施增加了行政負擔，延誤了治療的啟動，限制了患者的就醫途徑，並可能導致患者用藥依從性降低。因此，專科藥局的處方箋量和商機都會減少。

這種財務壓力迫使醫療系統限制藥品目錄的採用，並積極進行價格談判，阻礙了市場流動性。根據美國衛生系統藥劑師協會（ASHP）的數據，到2024年，醫生診室的藥品支出將年增14.6%，其中高成本專科藥物是主要成長動力。沉重的財務負擔迫使支付方收緊預算控制，造成一種限制性環境，使得醫療基礎設施難以消化快速推出的昂貴新療法，從而抑制了市場擴張。

市場趨勢

藥品福利管理機構 (PBM)、支付方和專科藥局之間日益加劇的垂直整合，正在從根本上重塑病患用藥管道和市場力量結構。大型健康保險公司正積極進行整合，以獲取高成本專科藥物的全部經濟價值，並透過其附屬的配藥管道有效地引導處方箋量。這種結構性轉變使垂直整合的公司對藥品目錄擁有更大的控制權，並使其能夠維持更高的利潤率，從而為爭奪有限的藥品供應而競爭的獨立藥房和醫院附屬藥房設置了巨大的障礙。根據《貝克爾醫院評論》2025年6月刊的預測，到2024年，由垂直整合的PBM機構擁有的前三大專科藥房將佔據專科處方藥收入的三分之二。

同時，人工智慧的快速應用正在革新專科藥局領域的用藥依從通訊協定和工作流程最佳化。相關人員正在部署先進的演算法來自動化複雜的行政任務，例如福利核實和事前核准，這些任務通常會延誤治療的啟動。這些人工智慧驅動的系統不僅消除了營運瓶頸，還能進行預測分析，識別用藥依從性有風險的患者，從而促進主動的臨床干預。為了反映這一趨勢，《管理式醫療與專科藥房雜誌》在2025年1月的報告中指出，92%的受訪醫療管理機構預測，未來五年內，人工智慧將應用於超過一半的事前核准審核中。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球特藥市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依所有權類型（獨立、醫院附屬、其他）
    • 依治療領域（癌症、類風濕性關節炎、血友病、C型肝炎、多發性硬化症、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美特藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲特藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區特藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲專科藥局市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲特藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球特藥市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • CVS Health Corporation
  • Walgreens Boots Alliance, Inc.
  • Express Scripts Holding Company
  • UnitedHealth Group Incorporated
  • Humana Inc.
  • BioScrip, Inc.
  • Diplomat Pharmacy, Inc.
  • Accredo Health Group, Inc.
  • Curant Health
  • Avella Specialty Pharmacy

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 8024

The Global Specialty Pharmacy Market is projected to expand from USD 128.41 Billion in 2025 to USD 192.82 Billion by 2031, achieving a compound annual growth rate of 7.01%. This sector focuses on the management and distribution of high-cost, high-touch medication therapies tailored for patients with rare, chronic, or complex conditions that demand specific administration and handling. The market's growth is chiefly propelled by an aging global population, the increasing prevalence of chronic diseases, and a robust pharmaceutical pipeline emphasizing orphan drugs and biologics. These foundational factors necessitate the specialized supply chain capabilities and clinical management inherent in specialty pharmacy models to guarantee patient safety and treatment adherence.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 128.41 Billion
Market Size 2031USD 192.82 Billion
CAGR 2026-20317.01%
Fastest Growing SegmentHospital-based
Largest MarketNorth America

Despite this positive growth trajectory, the market faces significant hurdles due to the high cost of therapies and strict reimbursement protocols that can impede patient access. The substantial financial weight of these treatments places immense pressure on health systems and payers, amplifying the need for robust cost-containment strategies. Illustrating the economic impact and management complexities associated with these essential treatments, the Academy of Managed Care Pharmacy reported that specialty medicines comprised 51% of total pharmacy spending in 2024.

Market Driver

Rapid innovation in gene therapies and biologics serves as a primary engine for the Global Specialty Pharmacy Market, fundamentally transforming the treatment landscape for rare and complex diseases. This momentum is defined by a strong pipeline of high-value treatments that require the distinct clinical expertise, patient support services, and cold-chain logistics central to specialty pharmacy operations. The focus on orphan drugs has intensified significantly, ensuring that niche patient populations gain access to targeted therapies that were previously restricted or unavailable. According to the FDA's '2024 New Drug Therapy Approvals' report released in January 2025, the agency approved 50 novel drugs in 2024, with therapies for rare diseases constituting over 50% of these approvals, a surge that reinforces the critical role of specialty pharmacies in safely delivering these life-changing regimens.

Concurrently, the proliferation of biosimilars following patent expirations is reshaping market dynamics by providing cost-effective alternatives to established biologic brands. As major blockbuster biologics lose exclusivity, health systems and payers are aggressively encouraging biosimilar adoption to alleviate the rising financial burden of specialty care while upholding high treatment standards. This shift not only lowers per-unit costs but also broadens patient access to critical therapies by reducing economic barriers; the Association for Accessible Medicines reported in September 2025 that biosimilars yielded $20.2 billion in savings for the U.S. healthcare system in 2024. Despite these savings, the aggregate demand for complex medications continues to fuel market expansion, with the American Society of Health-System Pharmacists noting in 2025 that overall U.S. pharmaceutical expenditures rose by 10.2% in 2024 to reach $805.9 billion.

Market Challenge

The elevated cost of therapy combined with rigorous reimbursement protocols creates a substantial barrier to the growth of the Global Specialty Pharmacy Market. Insurance providers and payers frequently deploy strict utilization management strategies to curb these rising expenses, often mandating step therapy protocols and complex prior authorization requirements. These measures generate administrative burdens and delay the initiation of treatment, which restricts patient access and can lead to lower medication adherence rates, ultimately reducing the volume of dispensed prescriptions and revenue opportunities for specialty pharmacies.

This financial strain compels health systems to limit formulary inclusions and negotiate aggressive pricing structures, thereby hampering market fluidity. Data from the American Society of Health-System Pharmacists indicates that drug expenditures for clinics rose by 14.6 percent in 2024 compared to the previous year, an increase driven primarily by high-cost specialty agents. This heavy economic burden necessitates tighter budget controls from payers, establishing a restrictive environment where market expansion is moderated by the healthcare infrastructure's inability to financially absorb the rapid introduction of expensive new therapies.

Market Trends

The increasing vertical integration of pharmacy benefit managers (PBMs), payers, and specialty pharmacies is fundamentally restructuring patient access mechanisms and market control. Major health insurers are actively consolidating operations to capture the full economic value of high-cost specialty therapies, effectively directing prescription volumes toward their own affiliated dispensing channels. This structural shift enables vertically integrated entities to tighten formulary management and retain higher margins, creating significant obstacles for independent and hospital-owned pharmacies striving to compete for limited distribution drugs. According to a June 2025 article in Becker's Hospital Review, the three largest specialty pharmacies-all owned by vertically integrated PBM organizations-accounted for two-thirds of specialty prescription revenue in 2024.

Simultaneously, the rapid adoption of artificial intelligence is revolutionizing medication adherence protocols and workflow optimization within the specialty pharmacy sector. Stakeholders are implementing advanced algorithms to automate complex administrative tasks such as benefits verification and prior authorization, which traditionally cause delays in therapy initiation. These AI-driven systems not only reduce operational bottlenecks but also facilitate predictive analytics to identify patients at risk of non-adherence, allowing for proactive clinical interventions. Reflecting this trend, the Journal of Managed Care & Specialty Pharmacy reported in January 2025 that 92% of managed care respondents anticipate AI will be incorporated into more than half of all prior authorization reviews within the next five years.

Key Market Players

  • CVS Health Corporation
  • Walgreens Boots Alliance, Inc.
  • Express Scripts Holding Company
  • UnitedHealth Group Incorporated
  • Humana Inc.
  • BioScrip, Inc.
  • Diplomat Pharmacy, Inc.
  • Accredo Health Group, Inc.
  • Curant Health
  • Avella Specialty Pharmacy

Report Scope

In this report, the Global Specialty Pharmacy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Specialty Pharmacy Market, By Ownership

  • Standalone
  • Hospital-Based
  • Others

Specialty Pharmacy Market, By Therapy Area

  • Cancer
  • Rheumatoid Arthritis
  • Hemophilia
  • Hepatitis C
  • Multiple Sclerosis
  • Others

Specialty Pharmacy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Specialty Pharmacy Market.

Available Customizations:

Global Specialty Pharmacy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Specialty Pharmacy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Ownership (Standalone, Hospital-Based, Others)
    • 5.2.2. By Therapy Area (Cancer, Rheumatoid Arthritis, Hemophilia, Hepatitis C, Multiple Sclerosis, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Specialty Pharmacy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Ownership
    • 6.2.2. By Therapy Area
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Specialty Pharmacy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Ownership
        • 6.3.1.2.2. By Therapy Area
    • 6.3.2. Canada Specialty Pharmacy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Ownership
        • 6.3.2.2.2. By Therapy Area
    • 6.3.3. Mexico Specialty Pharmacy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Ownership
        • 6.3.3.2.2. By Therapy Area

7. Europe Specialty Pharmacy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Ownership
    • 7.2.2. By Therapy Area
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Specialty Pharmacy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Ownership
        • 7.3.1.2.2. By Therapy Area
    • 7.3.2. France Specialty Pharmacy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Ownership
        • 7.3.2.2.2. By Therapy Area
    • 7.3.3. United Kingdom Specialty Pharmacy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Ownership
        • 7.3.3.2.2. By Therapy Area
    • 7.3.4. Italy Specialty Pharmacy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Ownership
        • 7.3.4.2.2. By Therapy Area
    • 7.3.5. Spain Specialty Pharmacy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Ownership
        • 7.3.5.2.2. By Therapy Area

8. Asia Pacific Specialty Pharmacy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Ownership
    • 8.2.2. By Therapy Area
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Specialty Pharmacy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Ownership
        • 8.3.1.2.2. By Therapy Area
    • 8.3.2. India Specialty Pharmacy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Ownership
        • 8.3.2.2.2. By Therapy Area
    • 8.3.3. Japan Specialty Pharmacy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Ownership
        • 8.3.3.2.2. By Therapy Area
    • 8.3.4. South Korea Specialty Pharmacy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Ownership
        • 8.3.4.2.2. By Therapy Area
    • 8.3.5. Australia Specialty Pharmacy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Ownership
        • 8.3.5.2.2. By Therapy Area

9. Middle East & Africa Specialty Pharmacy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Ownership
    • 9.2.2. By Therapy Area
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Specialty Pharmacy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Ownership
        • 9.3.1.2.2. By Therapy Area
    • 9.3.2. UAE Specialty Pharmacy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Ownership
        • 9.3.2.2.2. By Therapy Area
    • 9.3.3. South Africa Specialty Pharmacy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Ownership
        • 9.3.3.2.2. By Therapy Area

10. South America Specialty Pharmacy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Ownership
    • 10.2.2. By Therapy Area
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Specialty Pharmacy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Ownership
        • 10.3.1.2.2. By Therapy Area
    • 10.3.2. Colombia Specialty Pharmacy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Ownership
        • 10.3.2.2.2. By Therapy Area
    • 10.3.3. Argentina Specialty Pharmacy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Ownership
        • 10.3.3.2.2. By Therapy Area

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Specialty Pharmacy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. CVS Health Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Walgreens Boots Alliance, Inc.
  • 15.3. Express Scripts Holding Company
  • 15.4. UnitedHealth Group Incorporated
  • 15.5. Humana Inc.
  • 15.6. BioScrip, Inc.
  • 15.7. Diplomat Pharmacy, Inc.
  • 15.8. Accredo Health Group, Inc.
  • 15.9. Curant Health
  • 15.10. Avella Specialty Pharmacy

16. Strategic Recommendations

17. About Us & Disclaimer